SYROS PHARMAC.NEW DL-001
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute mye… Read more
Market Cap & Net Worth: SYROS PHARMAC.NEW DL-001 (0S90)
SYROS PHARMAC.NEW DL-001 (F:0S90) has a market capitalization of $798.74K (€778.14K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #36785 globally and #4588 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SYROS PHARMAC.NEW DL-001's stock price €0.03 by its total outstanding shares 26832500 (26.83 Million).
SYROS PHARMAC.NEW DL-001 Market Cap History: 2016 to 2025
SYROS PHARMAC.NEW DL-001's market capitalization history from 2016 to 2025. Data shows change from $3.18 Billion to $798.74K (-59.88% CAGR).
SYROS PHARMAC.NEW DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SYROS PHARMAC.NEW DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0S90 by Market Capitalization
Companies near SYROS PHARMAC.NEW DL-001 in the global market cap rankings as of March 19, 2026.
Key companies related to SYROS PHARMAC.NEW DL-001 by market ranking:
- Hydromer Inc (PINK:HYDI): Ranked #36776 globally with a market cap of $715.85K USD.
- SODEP-Marsa Maroc (BC:SODEP-Marsa-Maroc): Ranked #36777 globally with a market cap of $715.83K USD ( MAD7.19 Million MAD).
- Giant Motorsports Inc (PINK:BZRD): Ranked #36786 globally with a market cap of $712.16K USD.
- TGCC S.A. (BC:TGCC): Ranked #36787 globally with a market cap of $712.05K USD ( MAD7.15 Million MAD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #36776 | Hydromer Inc | PINK:HYDI | $715.85K | $0.27 |
| #36777 | SODEP-Marsa Maroc | BC:SODEP-Marsa-Maroc | $715.83K | MAD786.10 |
| #36786 | Giant Motorsports Inc | PINK:BZRD | $712.16K | $0.01 |
| #36787 | TGCC S.A. | BC:TGCC | $712.05K | MAD735.00 |
SYROS PHARMAC.NEW DL-001 Historical Marketcap From 2016 to 2025
Between 2016 and today, SYROS PHARMAC.NEW DL-001's market cap moved from $3.18 Billion to $ 798.74K, with a yearly change of -59.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €798.74K | -81.88% |
| 2024 | €4.41 Million | -97.48% |
| 2023 | €175.17 Million | +103.85% |
| 2022 | €85.93 Million | -89.39% |
| 2021 | €809.76 Million | -67.69% |
| 2020 | €2.51 Billion | +47.97% |
| 2019 | €1.69 Billion | +24.49% |
| 2018 | €1.36 Billion | -39.69% |
| 2017 | €2.26 Billion | -29.01% |
| 2016 | €3.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of SYROS PHARMAC.NEW DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $798.74K USD |
| MoneyControl | $798.74K USD |
| MarketWatch | $798.74K USD |
| marketcap.company | $798.74K USD |
| Reuters | $798.74K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.